bioSeedin’s Post

View organization page for bioSeedin, graphic

5,547 followers

𝐅𝐥𝐚𝐠𝐬𝐡𝐢𝐩 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐏𝐫𝐨𝐥𝐨𝐠𝐮𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐕𝐢𝐫𝐚𝐥 𝐏𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐟𝐨𝐫 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 Flagship Pioneering Flagship Pioneering's latest venture, Prologue Medicines Prologue Medicines, has launched with a $50 million investment to propel its innovative DELVE platform. DELVE, a cutting-edge proteome-assisted drug discovery technology, capitalizes on the expansive viral proteome to identify potential therapeutic molecules. Under the leadership of CEO Lovisa Afzelius Lovisa Afzelius, Prologue is dedicated to developing a robust pipeline of drug candidates, with a primary focus on cancer, metabolic, and immunology indications. Afzelius, alongside co-founders Theonie Anastassiadis and Hozefa Bandukwala, envisions Prologue as a frontrunner in leveraging viral proteins for medical advancements. With Noubar Afeyan as chairman, Prologue stands as a significant addition to Flagship's portfolio, which also includes Empress Therapeutics and ProFound Therapeutics. This strategic move reinforces Flagship's commitment to pioneering breakthroughs in the life sciences sector. #PrologueMedicines #DrugDiscovery #ViralProteins #FlagshipPioneering #DELVEPlatform #TherapeuticMolecules #HealthcareInnovation #InvestmentInScience

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics